Abstracts from USCAP 2020: Bone and Soft Tissue Pathology (37-109)
Jason L. Hornick,Rhonda K. Yantiss,Laura W. Lamps,Cme Subcommittee,Steven D. Billings,Raja R. Seethala,Ilan Weinreb,David Kaminsky,Zubair Baloch,Daniel J. Brat,Ashley Cimino‐Mathews,James R. Cook,Sarah Dry,William C. Faquin,Yuri Fedoriw,Karen Fritchie,Lakshmi Priya,Kunju Anna,Marie Mulligan,Rish K. Pai,David Papke,Vinita Parkash,Carlos Parra‐Herran,Anil V. Parwani,Narasimhan P. Agaram,Lei Zhang,Brendan C. Dickson,Cristina R. Antonescu,Rana Ajabnoor,Qi Yang,Brendan F. Boyce,Mazen Atiq,Andrew L. Folpe,Jessica L. Davis,Christopher D.M. Fletcher,Adrián Mariño‐Enríquez,Eli Lilly,Epizyme Consultant,Alfonso Mariño,Esther Baranov,Matthew Mcbride,Andrew M. Bellizzi,Cigall Kadoch,Eli Consultant,Davsheen Bedi,Svetlana A. Yatsenko,Virginia Miller,Karen E. Schoedel,Ivy John,Jacqueline Birkness,Dwayne L. Thomas,Lysandra Voltaggio,Elizabeth D. Thompson
DOI: https://doi.org/10.1038/s41379-020-0463-x
IF: 8.209
2020-01-01
Modern Pathology
Abstract:Background: GT are neoplams of perivascular smooth muscle differentiation, sharing variable histologic overlap with myofibroma (MF), myopericytoma (MP) and angioleiomyoma (AL).Despite their morphologic similarities, the genetic abnormalities suggest a dichotomy of the perivascular myoid tumor family into 2 categories: PDGFRB-mutant MF and MP and NOTCH-fusion positive GT.The latter observation was never validated in a larger study, to investigate its prevalence and correlation with clinical features.Design: 93 GT were selected after pathologic review and with available tissue for molecular studies.The tumors were also assessed for risk of malignancy based on current WHO criteria.All cases were tested by FISH method for NOTCH 1/2/3 and MIR143 gene abnormalities and 7 cases were also tested by targeted RNA sequencing.A control group of 41 other pericytic tumors (19 AL, 11 MP and 11 MF) were also investigated for these abnormalities.Results: FISH analysis revealed NOTCH gene rearrangements in 50 (54%) cases.The NOTCH-rearranged subset included 34 (68%) benign and 16 (32%) malignant GT.In the benign group, GT were mostly in soft tissue, and showed NOTCH2 gene rearrangements in 88%, fused to MIR143HG in 76% of cases.Rearrangements of NOTCH3 in 3 cases (with ACTB in 2 and MIR143HG in 1) and NOTCH1 in 1 case was seen.In the malignant group, GT were often located in the viscera (GI and lung, 67%) and showed NOTCH2 rearrangements in all except 2 cases (88%), with co-existent MIR143HG fusions in 69%.The remaining 2 malignant GT showed NOTCH1 gene fusions.Among the fusion-negative GT, 88% were benign, 9% of uncertain malignant potential and 2% were malignant.The most common location was the finger/subungual region, occurring in half of the cases.In the control group, 2 AL (11%) had NOTCH2 rearrangements, while 2 MP (18%) showed evidence of MIR143HG-NOTCH fusions (one involving NOTCH2 and the other NOTCH4).Conclusions: Rearrangements of NOTCH genes are seen in > half of GT, with MIR143HG-NOTCH2 being the most common fusion (73%).All except one malignant GT were positive for NOTCH fusions in contrast to only 47% of benign GT.Fusion-positive benign GT are overwhelmingly seen in males with a predilection for extremities, while the malignant GT occur mostly in visceral sites.Subungual GT lack NOTCH fusions, suggesting a different pathogenesis.Additional studies are required to investigate the genetic alterations in the fusion-negative cases.A small subset of AL and MP share the genetics of GT.